{
  "metadata": {
    "inference_mode": "ollama",
    "ollama_model": "als-lm-500m:q8_0",
    "ollama_url": "http://localhost:11434",
    "model_name": "als-lm-500m:q8_0",
    "generation_params": {
      "max_tokens": 512,
      "temperature": 0.0
    },
    "benchmark_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/questions.json",
    "timestamp": "2026-02-28T07:51:30.918449+00:00",
    "total_questions": 160
  },
  "responses": [
    {
      "question_id": "DRUG-001",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the FDA-approved drugs for ALS treatment and when they were approved.",
      "response": "\n\n\nThe study, we used a comprehensive data. We identified a single-based approach to identify the model of the model. The study, we used the data from the data, we have a comprehensive research on the model.\n\n\n\n\n\n\n\n\n\nand the first study, we conducted a comprehensive studies, we performed the study, we used the study, we identified a single-based approach to evaluate the model of the model.\n\n\n\n\n\n\n\n\nThe data, we have a comprehensive research on the study, we have a comprehensive analysis of the study, we used the data from the data, we will be performed using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe study, we have a single-based approach to evaluate the model, we will be used for the data.\n\n\n\n\n\n\nThe study, we have a comprehensive research on the data, we will be used in the data from the data.\n\n\n\n\n\n\nand the study, we have been developed a comprehensive studies, we have a single-based approach to evaluate the model of the data.\nthe data, we have a single-based approach for the data, and the data, we have a single-based approach to identify the data.\n\n\n\n\n\n\nThe data\nand the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\nthe study, we will be used to evaluate the model of the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data\nand the data\nthe\n\n\n\nthe\nthe\n\n\nthe\nthe\nthe\nthe\nthe data\n\n\nthe\n\n\n\n\n\nthe study, we have a single-based approach to identify the model.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the first-based approach for the data\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nand the model.\nthe\nThe study, we used a comprehensive data.\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\nthe\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-002",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how riluzole works to treat ALS at the molecular level.",
      "response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43)\nand the RNA sequencing. We used the RNA sequencing.\n\n\n\nthe RNA-binding protein-binding RNA-binding RNA-binding RNA-binding RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a single-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein (43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-003",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the mechanism of action of edaravone (Radicava) in ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the cellular dysfunction. The most common proteins, we identified in the development of the ALS. We found that the most common pathways, we have not be associated with ALS.\n\n\nand the most common proteins, we have a role in the disease progression of ALS.\n\n, we have a rare diseases, we have been reported that are known to be associated with ALS.\n\n, we have a recent study, we found that the most common mechanisms of the most common mutations in the most common in the most common genes, we have a role in the most common proteins, and ALS. We have a role in the most common genetic changes in the disease progression of the disease, we have been identified in AD, and tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the most common proteins, we have a role in AD, we identified in AD and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology. We have also known to be associated with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation of tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, and tau, tau pathology, tau pathology, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-004",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Name the drug prescribed for pseudobulbar affect (uncontrollable laughing or crying) in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-005",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the role of baclofen in managing ALS symptoms.",
      "response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the role in the disease progression of the disease progression of the disease.\n\n\n\n, we found that the most common genetic changes in the disease. We also be associated with the disease, we have been identified in the disease.\n\n\n\n, we have a rare neurodegenerative diseases, we have a rare diseases, and disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-006",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the results of the Bensimon et al. pivotal trial of riluzole in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a role in the impact on the role in the importance of the development of the role in the disease progression.\n\n\n\n\nThe authors have been reported that the most common mechanisms of the pathogenesis of the disease.\n\n\n\n\nand the most common mutations in the most common genetic changes in the most common pathways, we have a common proteins, we identified in the ALS. We found that the most common variants in the most common mutations in the ALS. The most common mutations in the ALS, we have a role of the disease progression of the disease.\n\n\n\n\n\nand the most common genetic changes in the most common mutations in the most common mutations in the most common proteins, we have been identified in the disease. We found that the most common variants in the most common mutations in the most common mechanisms underlying mechanisms, we have a role in ALS. The most common mutations in the aggregation of the most common pathways, we have a common proteins, we observed in the most common mutations in the most common proteins, we identified in the disease progression of the most common proteins, and ALS.\n\n\n\n\n\n\n\n\nand the most common mechanisms, we have been identified a rare diseases, we have a common proteins, we have a common pathways, we have a common mechanisms, we investigated the molecular modifications, we have a role in the development of ALS. We have a common proteins that the disease progression of ALS. The most common genetic and ALS, we have a common mutations in the most common proteins, we have been identified in the most common proteins, which is known to be associated with ALS.\n\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and Alzheimer's disease, and FTD, and FTD, and FTD",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-007",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe tofersen, its mechanism, and the specific ALS patient population it targets.",
      "response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role of the role in the role in the role in the role in the role in the role in the role in the role in the pathogenesis, we have a role in the underlying mechanisms that the importance of the development of ALS. The study, we found that the role in the disease progression of the most common genetic changes in the disease progression and FTD pathology in AD pathology in AD, we identified a role in AD pathology in AD pathology in AD, and tau pathology in AD pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\nand the aggregation is a role in AD, we have been reported that the most common mechanisms of tau pathology in AD, which are known as well as a role in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology. The most common tau pathology, we found that the aggregation of tau pathology in AD, tau pathology, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau, tau pathology, tau aggregation of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-008",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the common adverse effects associated with riluzole use in ALS patients.",
      "response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a common tau pathology in the tau aggregation of tau pathology, which are associated with tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology, we found that the tau aggregation of tau aggregation of tau pathology in AD, tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau aggregation of tau pathology and tau aggregation of tau aggregation of tau aggregation of tau pathology.\n\nand tau aggregation of tau pathology in the tau pathology in AD, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology and tau pathology in the tau aggregation of tau pathology.\n\n\n\nand the tau pathology is a common tau pathology, we found that tau pathology in AD, which are also known to be associated with tau pathology.\n\n\n\n\nand tau pathology in the tau pathology in the tau aggregation of tau pathology in the tau pathology, and tau pathology, tau aggregation of tau plaques, tau pathology, tau pathology, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau pathology, which are a common tau pathology.\n\n\nand tau-43 is a role in AD, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, and tau pathology, tau aggregation of tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau aggregation, tau aggregation, tau pathology.\nand tau aggregation is a common tau-43, which are known as well as a role in AD.\n\n\n, we have been identified in the tau pathology and tau pathology in AD, tau pathology of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-009",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe AMX0035 (Relyvrio) and the results of the CENTAUR clinical trial for ALS.",
      "response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\nThe study, we have been reported that the role in the disease progression of the disease progression and FTD.\nand the most common genetic diagnosis of AD pathology, we identified in AD, and tau pathology in AD, and tau pathology, and tau pathology. We found that the tau pathology, we investigated the AD pathology in AD pathology in AD, we have a significant differences between AD pathology in AD pathology in AD pathology in AD pathology in AD, we observed in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD.\n\nand the most common tau pathology in AD and AD, we identified a role of tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we have been reported that tau pathology in AD, we found that tau pathology in AD pathology in AD, and tau pathology, and tau pathology in AD.\n\nand tau pathology in AD, we investigated the most common tau pathology in AD, we identified a role of tau pathology in AD pathology in AD pathology, we have been identified in AD pathology in AD, we have been reported that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD and tau pathology.\n\n\nand the tau pathology, we investigated the most common tau pathology, we have a role of tau pathology in AD, we have been identified in AD, we have been identified in AD, we have been reported that tau pathology in AD, we have been identified in AD pathology, we found that tau pathology, and tau pathology.\nand tau pathology, we investigated the aggregation of tau pathology in AD, we have a role in AD, we have been shown that tau pathology, we have been identified in AD pathology, we have been reported that tau pathology in AD, we have been linked to be associated with AD, tau pathology in AD pathology, and tau pathology.\nand the tau pathology, we found that tau pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we identified a role of tau pathology in AD pathology in AD, tau pathology in AD pathology in AD, tau pathology, tau pathology, and tau pathology.\n\n\n\nand tau pathology, we have been reported that tau pathology, we found that tau pathology, we investigated",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-010",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe masitinib and explain how it is proposed to help in ALS treatment.",
      "response": "\n\n\nThe study, we have a recent study, we found that the first study, we identified a significant differences in the disease progression of AD pathology. The most common tau pathology in AD patients with AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology in AD, and tau pathology, and tau, and tau, tau pathology, tau, tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, tau, tau, and tau, tau, tau, and tau, tau, tau, tau, tau, and tau pathology, and tau, and tau, tau, and tau, tau, tau, tau, tau, tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-001",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Identify the most frequently mutated gene in familial ALS cases.",
      "response": "\n\n\n\n\n, we have a rare disease. We found that the most common genetic and FTD.\n\n\n\nThe most common variant in the most common mutations in the most common protein in the tau pathology in the tau aggregation of tau pathology. The tau is also known to be associated with the tau pathology, which are the tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation, and tau pathology.\n\n\n\nand tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation in the tau aggregation of tau aggregation, and tau aggregation, and tau aggregation of tau aggregation of tau aggregation, which is a common tau pathology.\n\n\n\n\n\n, we have been identified by the aggregation of tau pathology in the tau aggregation of tau aggregation of tau pathology in AD, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau aggregation of tau pathology. We found that are also known to be associated with tau pathology and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\nand tau aggregation of tau pathology in the tau pathology, we have a common tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology.\n\n\nand tau aggregation of tau plaques, we found that tau aggregation of tau aggregation of tau pathology in AD, we have been identified in the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology in the tau pathology in the tau pathology in AD pathology. We investigated the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, we have a role in the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\nand tau pathology is a common tau pathology and tau pathology, we investigated the tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology. We have been identified in the tau pathology in the tau plaques, which is a role in the tau pathology in the tau pathology and tau pathology in AD pathology in the tau pathology in the tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-002",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the role of SOD1 mutations in ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the ALS patients with SMA patients with SMA patients. We found that the ALS patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients.\n\n\n\n\n, we have a rare disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with SMA, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, with AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-003",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the TARDBP gene, its protein product, and its role in ALS.",
      "response": "\n\n\n\nThe most common variant of the RNA-43, and tau aggregation, and tau pathology, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau-43, and tau, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau pathology.\n\n\n\n\n\nThe most common mutations in AD, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-004",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the function of FUS and how FUS mutations lead to ALS.",
      "response": "\n\n\n\n\n\n, we have a rare disease. We found that the most common TDP-43 pathology in the TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-005",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the proportion of ALS cases that are familial (inherited) versus sporadic.",
      "response": "\n\n\n\n\nThe study, we used a comprehensive data. We have a significant differences in the disease progression and FTD. The results, we found that the most common genetic changes in AD pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-006",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe TBK1 and explain its connection to ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression. We have a common genetic mutations in AD pathology. The most common tau aggregation of tau pathology in AD pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-007",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the molecular mechanisms by which the C9orf72 hexanucleotide repeat expansion causes ALS.",
      "response": "\n\n\n\n\nThe most common in the SMN protein and FUS, and FUS, and FUS, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-008",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Name the protein product of the SOD1 gene and describe its normal function.",
      "response": "\n\n\n\n\n\n\nand the RNA-binding protein, which is a protein. The RNA-binding protein (Fig. 5).\n\n\na is the RNA-binding protein (Fig. 5A) is a protein in the RNA-binding protein (Fig. 5B).\n\n\n\n\n\n\nthe RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein, which is the RNA-binding protein (Fig. 5). The RNA-binding protein (Fig. 5C) is a protein in the RNA-binding protein (Fig. 5B) is the RNA-binding protein (Fig. 5-43 and the RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein (Fig. 5).\n\n\n\n\n\n\nand the RNA-binding protein, which is a protein in the RNA-binding protein (Fig. 5). The RNA-binding protein (Fig. 5B) and the RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein (Fig. 5C) is the RNA-43 (Fig. 5D) is the RNA-binding protein (Fig. 5A) is a protein in the RNA-binding protein (Fig. 5B) and the RNA-binding protein (Fig. 5A) is also known to the RNA-binding protein (Fig. 5C).\n\n\n\n\nand the RNA-binding protein (Fig. 5A) is the RNA-43, which is a protein in the RNA-binding protein (Fig. 5B), and the RNA-binding protein (Fig. 5D). The RNA-binding protein (Fig. 5).\n\n\n\n\na) is also known to the RNA-binding protein (Fig. 5A) is the RNA-43, which is a protein (Fig. 5C) is the RNA-binding protein (Fig. 5B), the RNA-binding protein (Fig. 5A) is the RNA-binding protein (Fig. 5).\n\n\nand the RNA-binding protein (Fig. 5). The RNA-binding protein of the RNA-43, we found that the RNA-binding protein in the RNA-binding protein (Fig. 5B), and the RNA-binding protein (Fig. 5A) is a protein (Fig. 5C). We investigated the RNA-binding protein-binding protein (Fig. 5D).\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-009",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the function of BRCA3 and its contribution to ALS.",
      "response": "\n\n\n\n\n\n\n\n\nThe study, we investigated the study, we conducted a comprehensive studies, we have been identified in the clinical trials.\n\n\n\n\n\n\n\n\n\n, we have a recent study, we have a comprehensive research that the study, we have a comprehensive research on the study, we have been developed a comprehensive research.\n\n\n\n\nThe study, we have been identified in this study, we have been identified a comprehensive studies, we have a comprehensive research that the study, we have a comprehensive research, we have a comprehensive research.\n",
      "tokens_generated": 122,
      "is_coherent": true
    },
    {
      "question_id": "GENE-010",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the genetic overlap between ALS and frontotemporal dementia (FTD).",
      "response": "\n\n\n\n\n\n\n\n, we investigated the disease progression of the disease. We have a role in the disease progression of the disease progression of the disease.\n\n\nThe most common neurodegenerative diseases, we identified a rare neurodegenerative diseases, and disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and FTD, and AD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-001",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the El Escorial diagnostic criteria for ALS and its classification levels.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-002",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare the Awaji-shima criteria with the revised El Escorial criteria for ALS diagnosis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-003",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the clinical signs of upper motor neuron involvement in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n, and other cases, and are associated with SMA, and FTD, and FTD, and FTD, and FTD.\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-004",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the clinical signs of lower motor neuron involvement in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-005",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the electromyography (EMG) findings typically seen in ALS patients.",
      "response": "\n\n, we investigated the study of the study. We have a significant differences between the disease progression and AD. The results in the most common genetic changes in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology.\n\n\n\n, we identified a recent study, we found that the AD patients with AD pathology in AD pathology in AD pathology in AD pathology in AD, and tau pathology in AD, and tau pathology in AD pathology in AD pathology in AD pathology. We also associated with AD, we have a significant correlation between AD pathology in AD, we found that the AD pathology in AD, we identified in AD patients with AD pathology in AD pathology in AD pathology in AD pathology in AD, and AD, and AD pathology in AD pathology in AD, tau pathology in AD, and tau pathology.\n\n\nand tau pathology in AD, we investigated the AD, we have a role of tau pathology in AD, we found that tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD pathology. We also identified a significant differences in AD and tau pathology in AD pathology in AD pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD, we found that tau pathology in AD, we have a role in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD.\n\n\n\n\n\nand the most common tau pathology, we identified a significant correlation between tau pathology in AD and tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-006",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the Gold Coast criteria and how they simplify ALS diagnosis compared to earlier criteria.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the disease progression of the disease.\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n\n\n, we have a rare neurodegenerative diseases, we have a common genetic and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau pathology, and tau, and tau, and tau, and tau, tau, and tau, tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-007",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the key conditions that must be ruled out when diagnosing ALS.",
      "response": "\n\n\n\n\n\n\n\nThe study, we have a significant differences in the disease progression of the disease.\n\n\n\n\n, we found that the most common genetic mutations in the disease. We also associated with the most common variants in the disease and the disease.\n\n\n\n\n\nand the most common TDP-43, we identified a TDP-43, we have a TDP-43, we investigated the TDP-43 pathology in the TDP-43, we found that TDP-43 aggregation of TDP-43, we observed in the TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-008",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe Kennedy disease and explain how it is distinguished from ALS.",
      "response": "\n\n\n\n\n\nThe most common genetic mutations in the disease, and other neurodegenerative diseases, and disease, and Alzheimer's disease, and FTD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer disease, and FTD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-009",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the Brainbridge classification system for ALS diagnostic subtypes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-010",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the average diagnostic delay from first symptoms to confirmed ALS diagnosis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-001",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the ALSFRS-R scale and explain its role in ALS clinical trials.",
      "response": "\n\n\n\n\n\nThe study, we investigated the study, we conducted a comprehensive studies, we have been identified a comprehensive research. The study, we used to identify the importance of the potential for the future research.\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive research on the clinical trials, we have a comprehensive research, we have a comprehensive research and clinical trials, we have been developed a comprehensive research.\n\n\n\nThe study, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research, we identified in the study, we have a comprehensive research.\n",
      "tokens_generated": 134,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-002",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the VALOR trial design for tofersen in SOD1-ALS and its key results.",
      "response": "\n\n\n\n\nThe study, we investigated the first study, we used a comprehensive studies. We have a comprehensive research that the clinical trials, we have been identified a comprehensive research. The study, we have demonstrated that the potential of the importance of the development of the development of the development of the development and clinical trials.\n\n\n\n\nThe authors have shown that the use of the limitations, we have a promising therapeutic potential for the need to the treatment in the current studies.\n\n\n\n\n\n\n\n\n\n\nand the study, we have been developed a comprehensive research on the study, we have a comprehensive and clinical trials, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research, we have a comprehensive research that the study, we have been developed a comprehensive understanding of the use of the importance of the need for the clinical trials.\n\n",
      "tokens_generated": 205,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-003",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List and explain the primary efficacy endpoints typically used in ALS clinical trials.",
      "response": "\n\n\n\n\n\n\n\nThe study, we have a significant of the first study. The study, we found that the study, we investigated the study, we have a significant differences between the disease progression. We identified a significant correlation between the disease and FTD patients with AD pathology in the disease progression of AD.\n\n\n\n\nand the most common genetic diagnosis of AD, we have been reported that the disease progression of tau pathology.\n\n, we found that the most common tau pathology in AD, we investigated the disease progression of AD. We identified a recent study, we have a significant correlation between the role of AD pathology in AD and tau pathology in AD patients with AD, we found that the tau pathology in AD pathology in AD pathology in AD pathology in AD, and tau pathology in AD, and tau pathology in AD, and tau pathology in AD, and tau pathology.\n\n\n\n\nand tau pathology in AD, we investigated the role of tau pathology in AD, we have a common tau pathology in AD, we identified in AD pathology in AD, we found that tau pathology in AD, tau pathology in AD pathology in AD, tau pathology in AD pathology, tau pathology in AD and tau pathology. We found that tau pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD, we have a role of tau pathology in AD pathology in AD pathology in AD, tau pathology in AD pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology in AD, and tau pathology in AD, tau pathology.\n\nand tau pathology, we found that tau pathology in AD, we investigated the tau pathology in AD pathology in AD, we have been identified a role of tau pathology in AD pathology in AD pathology, tau pathology in AD pathology in AD pathology in AD, tau pathology in AD and tau pathology in AD, tau pathology. We also known to be associated with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau, tau pathology, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-004",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the clinical trial that resulted in riluzole being approved for ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-005",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the key Phase 3 clinical trial of edaravone for ALS and its results.",
      "response": "\n\n\n\nThe study, we have a common genetic diagnosis. The study, we identified a comprehensive studies, we have been reported that the disease progression of the disease.\n\n\n\n, we have a recent study, we have a rare neurodegenerative diseases, we have a role in the disease, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and tau, and PD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and tau, and PD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and tau, and PD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and tau, and PD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and tau, and PD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD, and AD",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-006",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the platform trial concept and describe its application in ALS clinical research.",
      "response": "\n\n\n\n\n\n\n\n\n\nThe study, we identified a comprehensive research that the first study of the study. The study, we have been reported that the clinical trials, we have a comprehensive studies, we have been identified in the disease progression of AD. We have a recent study, we have a common genetic and AD patients with AD pathology, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\n\n\nand the most common tau pathology in AD, we have been identified a recent study, which is a role of tau pathology.\n\n\n\nThe most common genetic mutations in AD, we have been reported that tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-007",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the outcomes of NCT09876543 studying neuromax for ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-008",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain what ClinicalTrials.gov is and its role in ALS clinical research.",
      "response": "\n\n\n\n\nThe study, we have been reported that the importance of the development of the disease progression of the disease. The most common genetic mutations in the disease.\n\n\n\n\n\nand the most common genetic variants in the most common mechanisms, we have a rare diseases, we have been identified in the disease.\n\n\n\n\nThe most common genetic and genetic mutations in the disease, we have been identified in the disease, we have a common genetic mutations in the disease. The most common genetic variant in the most common genetic variants in the disease, we have a common genetic mutations in the disease, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, we have a common genetic and FTD, and FTD, we identified a rare neurodegenerative disease.\n\n\n\n\n\nThe most common genetic diagnosis of the disease, we have been identified a rare neurodegenerative diseases, we have been identified a rare neurodegenerative diseases, we have been identified in the disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD. We have been reported that are known as a common genetic mutations in AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-009",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the main challenges that complicate the design and execution of ALS clinical trials.",
      "response": "\n\n\n\n\n\nThe study, we identified a comprehensive research on the importance of the development of ALS.\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the disease progression of ALS.\n, we found that the most common genetic mutations in the disease.\n\n, we have a rare neurodegenerative diseases, we have a common genetic and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-010",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain how neurofilament light chain (NfL) is used as a biomarker in ALS clinical trials.",
      "response": "\n\n\n\nThe study, we have been reported that the first study of the most common genetic variants in the disease. The most common genetic mutations in the most common in the most common mutations in the disease progression of the disease.\n\n\n\n\n\n, we investigated the most common genetic changes in the molecular mechanisms for the role in the development of the disease progression and disease progression, we have a common pathways, we identified a common disease. We have been reported that the disease, we have not be associated with the disease.\n\n\n\n\nand the most common mutations in the disease, we have a rare neurodegenerative diseases, we have a common genetic changes in the disease, we have a common disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD. We found that the most common genetic mutations in AD, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-001",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the concept of excitotoxicity and its role in ALS motor neuron death.",
      "response": "\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "MECH-002",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe TDP-43 pathology and explain why it is considered a hallmark of ALS.",
      "response": "\n\n\n\n\nThe most common genetic diagnosis, with the disease, and FTD, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer-ALS, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease, and Alzheimer's disease",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-003",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of oxidative stress in ALS pathogenesis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\nThe study, we investigated the potential of the role in the development of ALS.\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the role in the disease progression of the disease.\n, we found that the most common genetic and ALS.\n\n, we have a significant differences between the most common mutations in the disease. We have a rare neurodegenerative diseases, we identified a common genetic changes in the disease.\n\n\n\n, we have been reported that the most common genetic diagnosis of the disease, we have a common genetic variants in the disease.\n\n\n\n, we investigated the role for the disease progression of the disease, we have a common mutations in the disease, and FTD. We have a rare neurodegenerative diseases, we identified a common genetic changes in the disease, we have a common genetic mutations in the disease, we have been reported that the disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n, we found that the most common genetic mutations in AD, we identified a rare neurodegenerative diseases, we have a common genetic mutations in the disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n\n\n, we have been reported that the most common genetic mutations in AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD,\n\n,\n,\n,\nand the most common genetic mutations in AD,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-004",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain what protein aggregation means in the context of ALS and which proteins are involved.",
      "response": "\n\n\n, we have a role of the disease progression of AD. The most common mechanisms that the development of tau pathology in AD.\n\nand the aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation and tau aggregation of tau aggregation, and tau aggregation of tau aggregation, and tau aggregation, which is known to be associated with tau aggregation.\n\n\n\n\n\n, we have been identified a role in AD, we investigated the aggregation of A\u03b2-associated tau pathology. We found that the aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation and tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation in AD.\n\n\n\nand tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau pathology, we found that the aggregation of tau aggregation of tau aggregation of tau aggregation of tau pathology in AD, which is a role in AD and tau pathology in AD, and tau pathology in AD, and tau pathology in AD, and tau pathology.\n\n\n\nand tau pathology in AD-43 aggregation of tau aggregation of tau pathology in AD, we found that the aggregation of tau pathology in AD, we have been reported that tau pathology in AD pathology in AD, which is a role in AD, with tau pathology in AD, and tau pathology in AD, and tau pathology.\n\n\nand tau pathology in AD, we investigated the most common tau pathology in AD, we found that tau pathology in AD, tau aggregation of tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology. We have a role in AD, we identified a recent study, we investigated the tau pathology in AD, we found that tau pathology in AD pathology in AD pathology in AD pathology in AD, tau pathology, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\n\nand tau pathology, we have a role of tau pathology in AD and tau pathology in AD, tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD, tau pathology in AD pathology, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology.\n\nand tau pathology, we have been identified a role in AD and tau pathology, tau pathology, tau pathology, tau pathology, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-005",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the contribution of non-neuronal glial cells to ALS disease progression.",
      "response": "\n\n\n\nThe most common in the most common in the disease, and FTD, and AD, and PD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-006",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how defects in RNA processing contribute to ALS pathogenesis.",
      "response": "\n\n\n\n\n, we investigated the potential of the role in the development of the disease progression and disease.\n\n\n\n\n\nThe most common mutations in the molecular modifications, we have been identified a novel mechanisms that are essential for the aggregation of the cellular homeostasis.\n\n\n\nand the RNA-binding protein (43) is a complex, which is a crucial for the RNA-associated proteins, which is a role in the RNA-binding protein.\n\n\n\n\n\n\n\n\n\n\nand the RNA-binding protein, we have a common RNA-binding protein, we investigated the RNA-binding protein-binding protein-binding protein (Figure 5). The RNA-43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein in the RNA-binding protein-binding protein.\nand the RNA-binding protein-binding protein-binding protein (Figure 5A) and RNA-binding protein (Figure 5B, we identified a protein (Figure 5). The RNA-43-associated TDP-43-43-43 aggregation of TDP-43, we found that TDP-43-43 aggregation in the TDP-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, we found that TDP-43-43 aggregation of TDP-43-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43, we found that TDP-43-43-43-43 aggregation of TDP-43-43-43-43-43-43-43-43-43 and TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 aggregation in the TDP-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-007",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of autophagy dysfunction in ALS pathogenesis.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the role in the role in the role in the role in the disease progression of the disease.\n\n\n\n\n\n\n, we have a common mechanisms underlying mechanisms of the pathogenesis of ALS.\n, we found that the most common mutations in the most common proteins, and ALS.\n\n\n, we identified a novel mechanisms, we investigated the molecular modifications, we provide a role in the role in the role in the role of the role in the role in the role in the role in the development of the disease progression of the disease.\n\n\n\nand the role in the role in the role in the role in the role in the role in ALS, we have a common mechanisms of the molecular mechanisms that the aggregation of the pathogenesis of the role in the role in the role in the role in the role in the development of the progression and the disease.\n\n\n\n\n\nand the most common proteins, we identified a crucial role in the disease. We have been identified a common mutations in the disease, we investigated the molecular mechanisms that the role in the role in the disease progression of the disease progression of the disease.\n\n\n\n\n, we have a novel therapeutic potential of ALS, we have shown that the development of the disease.\nand the most common proteins, we found that the aggregation of the aggregation of the aggregation of the aggregation of the aggregation and the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation. We identified a role in the ALS. The most common proteins, we have been identified a crucial for the disease progression of the development of the disease.\n\n\n\nand the most common proteins that the most common proteins,\n,\n,\n,\n,\nand the most common proteins,\n,\nthe aggregation of the disease.\n, we investigated the molecular modifications in the role of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation.\nand the most common proteins, we identified a role in the disease progression of ALS. We have a novel mechanisms that the development of ALS.\n\nand the molecular modifications of the aggregation of the aggregation of the aggregation of the aggregation",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-008",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how SOD1 protein misfolding leads to motor neuron damage in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "MECH-009",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the role of neuroinflammation in ALS disease progression.",
      "response": "\n\n\n\n\n, we investigated the most common mechanisms of the pathogenesis of the disease.\n\n\n\n\n\n\n\n\n\n, we have been identified a common mechanisms that the disease.\n\n, we found that the most common genetic and the disease, we have a role in the disease.\n\n\nand the disease is a rare neurodegenerative diseases, we have a common genetic mutations in the disease progression of the disease.\n\n\n\n, we have a common genetic mutations in the disease, we identified a common genetic and FTD, we found that are associated with AD pathology, and tau pathology, and tau pathology, and tau aggregation, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, and tau, tau, and tau, and tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-010",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the PLK4 kinase signaling cascade in ALS motor neuron degeneration.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-001",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year riluzole received FDA approval for treating ALS.",
      "response": "\n\n\n\n\n\n\n\n\n, we conducted a single-based sequencing (1) and RNA-43 (43 (43), and FUS (43 (43) and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-002",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year edaravone (Radicava) received FDA approval for ALS treatment.",
      "response": "\n\n\n\nThe study, we used the study. The study, we conducted a single-based data collection, and the data, we used to assess the model.\n\n\n\n\n\n\n\n\n\n\n\nThe study, we performed the study, we used the data from the data, we used the data, we used the data, we used the data, we identified a comprehensive studies. We have a comprehensive data, we used the data, we conducted a comprehensive and the data, we used to evaluate the data. The study, we have a comprehensive data, we performed the data, we used the data, we used the data from the data, we used for the data, we identified a comprehensive data, we used the data, we used the data, we used the data, we will be available in the data.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive information, we have been developed a comprehensive studies, we have a comprehensive data, we have a comprehensive and the data, we have a comprehensive research. We have a comprehensive data, we used to evaluate the data from the data, we will be available in the data.\n\n\n\n",
      "tokens_generated": 248,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-003",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when ALS was first clinically described and by whom.",
      "response": "\n\nThe study, we have a significant differences in the disease progression of AD pathology.\n\n\n, we found that the most common tau pathology in AD patients with AD pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, tau aggregation, and tau pathology, and tau pathology.\n\n\nand tau pathology, we found that the tau pathology in AD pathology in AD patients with AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau pathology, tau, tau, tau aggregation, tau, tau, and tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-004",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the year SOD1 mutations were first identified as a cause of familial ALS.",
      "response": "\n\n\n\n\n\nThe study, we investigated the study, we performed a single-old controls. The study, we used the first study, we analyzed the study, we conducted using a single-specific RNA sequencing. We used the RNA-seq analysis of the RNA-43 and RNA-type RNA-binding protein.\n\n\n\n\n\n\n\n\n\nThe RNA-43-43-43-43-43-43-43-43-43-43-43, we identified a single-length TDP-43 (43) and TDP-43 (43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-005",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when the C9orf72 hexanucleotide repeat expansion was identified as a genetic cause of ALS.",
      "response": "\n\n\n\n\nThe study, we found that the disease progression in the disease. We have a significant difference between the most common variant in the disease. The results from the most common variants in the disease and the disease.\n\n\n\n\n\n\nand the first study, we identified a single-specific RNA sequencing (43) and FUS (43, and tau pathology, tau aggregation, and tau pathology, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-006",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain when and why ALS became known as Lou Gehrig's disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-007",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Provide the dates of the original El Escorial criteria and their major revisions.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the impact on the importance of the development of the context of the use of the patient.\n\n\n\n\n, we have been reported that the most common genetic changes in the disease.\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative diseases, and the disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and FTD,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-008",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when the Ice Bucket Challenge occurred and its impact on ALS research.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-009",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when the ALSFRS-R was developed and explain how it improved upon the original ALSFRS.",
      "response": "\n\n\n\nThe study, we conducted a comprehensive data from the study. The study, we used the study, we identified a comprehensive studies, we have a comprehensive research that the data, we have a comprehensive data. We have a comprehensive analysis of the data, we have been reported that the data, we have a significant correlation between the data, we have a more common and clinical trials, we have a comprehensive data.\n\n\n\n\n\n\nThe study, we identified a comprehensive studies, we used a comprehensive research on the data, we have a comprehensive data from the data, we have a comprehensive analysis of the data, we have a comprehensive studies, we have a comprehensive data, we will be available in the data. We have a comprehensive and clinical trials, we have a comprehensive study, we have a comprehensive data, we have been identified a comprehensive research on the data, we have a comprehensive research.\n\n\n\n",
      "tokens_generated": 191,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-010",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Determine whether riluzole received FDA approval for ALS treatment in 2005.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-001",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the approximate global incidence rate of ALS.",
      "response": "\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-002",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the average age at which ALS symptoms typically begin.",
      "response": "\n\n\nThe study, we used a single-based approach for the model. The data were performed using the data from the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{wasysym}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{wasysym}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{amsfonts}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{upgreek}\n\\usepackage{",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-003",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the male-to-female ratio in ALS and whether it differs by disease subtype.",
      "response": "\n\n\nThe study, we investigated the study, we identified a comprehensive studies, we have been reported that the clinical trials. We have demonstrated that the importance of the potential for the future research.\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive research on the study, we have a comprehensive studies, we have identified a comprehensive and clinical trials, we have been developed a comprehensive research. The study, we have a comprehensive research that the study, we have a comprehensive research, we have a comprehensive understanding of the study, we have a comprehensive research.\n\n",
      "tokens_generated": 131,
      "is_coherent": true
    },
    {
      "question_id": "EPI-004",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the median survival time from symptom onset and from diagnosis for ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-005",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the unusually high ALS prevalence historically observed in Guam and its implications.",
      "response": "\n\n\n\n\n\n\n, we have a role in the use of the treatment.\n\n\n\nThe study, we investigated the study, we found that the study, we have a significant differences between the impact on the importance of the potential for the importance of the importance of the importance of the importance of the development of the importance of the importance of the context of the role in the importance of the importance.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive studies, we have been identified in the study, we have a comprehensive research. We have a significant differences in the study, we have a more common genetic and clinical trials, we have a comprehensive data from the data, we have a comprehensive research. The study, we have a comprehensive studies, we have a comprehensive research, we have a comprehensive research, we have been identified a comprehensive research that are available for the data, we have a comprehensive research.\n\n\n\n\n\n\nThe study, we have a comprehensive research, we have a comprehensive research and clinical trials, we have a comprehensive research, we have a comprehensive studies, we have a comprehensive research on the study, we have been identified in the literature. We have been developed a comprehensive research, we have a comprehensive research.\n\n\n\n\n",
      "tokens_generated": 267,
      "is_coherent": true
    },
    {
      "question_id": "EPI-006",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the environmental and lifestyle factors that have been linked to increased ALS risk.",
      "response": "\n\n\n\nThe most common mechanisms of the development of the disease, such as a common genetic mutations in the disease.\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-007",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence regarding ALS risk in professional athletes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-008",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the two primary clinical presentations of ALS based on where symptoms first appear.",
      "response": "\n\n\n\n\n\n, we investigated the study, we identified a comprehensive studies, we have been reported that the role in the disease progression of the disease.\n\n\n\n, we have a recent study, we found that the most common genetic and the disease, we have a significant differences between the disease. We also found that the clinical trials, we have a more common genetic diagnosis, we have not be associated with AD pathology.\n\n, we identified a role of AD, we investigated the importance of tau pathology in AD pathology, and tau pathology.\n\nand tau aggregation, we identified a role in AD pathology in AD, which is a role in AD pathology in AD pathology in AD pathology in AD, and tau pathology in AD pathology in AD pathology in AD, and tau pathology in AD, and tau pathology, and tau pathology in AD, and tau pathology in AD.\n\n\nand the most common tau pathology in AD, we have been identified in AD, we have a role of tau pathology, which is a common tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology in AD, tau aggregation, tau pathology, and tau pathology, tau pathology. We found that the most common tau pathology in AD, we investigated the tau pathology in AD, we have been identified in AD, we have a role of tau pathology in AD pathology, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\n\n\nand tau pathology, we found that tau pathology, we investigated the aggregation of tau pathology in AD, we identified in AD, we have a role in AD and tau pathology, tau pathology in AD pathology in AD, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology.\nand the aggregation of tau pathology, tau pathology, tau pathology, we have a role in AD, and tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau pathology, tau pathology in AD, tau pathology, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-009",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence linking military service in the Gulf War to increased ALS risk.",
      "response": "\n\n\n\n\n* P.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 2,
      "is_coherent": false
    },
    {
      "question_id": "EPI-010",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the epidemiological evidence for the ALS cluster among Faroe Islands fishing communities.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-001",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the criteria and guidelines for starting non-invasive ventilation (NIV) in ALS patients.",
      "response": "\n\n\nThe study, we have a study, we found that the study, we used to evaluate the need for the importance of the future research.\n\n\n\n\n\n\nThe study, we conducted a comprehensive studies, we identified a comprehensive and clinical trials, we have been developed a comprehensive understanding of ALS. We have a comprehensive research on the study, we have been identified in the study, we have been used to identify the need for AD.\n\n\n\n\n",
      "tokens_generated": 99,
      "is_coherent": true
    },
    {
      "question_id": "CARE-002",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the indications and timing for PEG tube placement in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-003",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the multidisciplinary approach to ALS care and its benefits.",
      "response": "\n\n\n\n\n\n\n\n\n\n\nThe study, we have a significant correlation between the first% of the first% of the first-based approaches. The study, we identified a comprehensive studies, we used the data, we conducted using the data. We have been reported that the study, we have a single-based sequencing (Supplementary Table 1.5, and the most common gene expression in the RNA-specific RNA-binding protein (Figure 5).\n\n\n\nThe RNA-binding protein (43) is a protein (Figure 5). The RNA-binding protein (Figure 5).\n\n\nand RNA-binding protein (Figure 5).\n\n\nand the RNA-binding protein, we identified a single-seq (Figure 5A) and RNA-binding protein (Figure 5B) and RNA-binding protein (Figure 5A) and RNA-43-binding protein (Figure 5A) and RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5).\n\n\nand the RNA-binding protein-binding protein (Figure 5A, we identified a RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5B) and RNA-43 (Figure 5A) and RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5).\n\n\n\n\nand the RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5A) and RNA-binding protein (Figure 5B), we identified a RNA-43, we found that the RNA-binding protein (Figure 5). The RNA-binding protein in the RNA-binding protein (Figure 5C) and RNA-binding protein (Figure 5A) and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-binding protein (Figure 5A) and FUS-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (Figure 5A) and FUS-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "CARE-004",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the communication aids and assistive technology used by ALS patients who lose speech.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-005",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Discuss the decision-making around tracheostomy and long-term mechanical ventilation in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-006",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how physical therapy helps ALS patients manage their symptoms.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-007",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the palliative care strategies employed for ALS patients in the terminal phase.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-008",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the treatment options for excessive saliva (sialorrhea) in ALS patients.",
      "response": "\n\n\n\n\n\nThe study, we conducted a cohort of the first study. The study, we used the study, we performed the study, we identified a comprehensive data from the study. We have a single-based sequencing (Supplementary Table S1).\n\n\n\n\n\n\nWe found that the ALS patients with SMA patients with ALS patients with ALS patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA patients with SMA, and FTD. The most common genetic variants in the disease progression of the disease. We have a rare disease, we identified a rare disease-43, and FUS, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n\n\n\n\nThe most common genetic variants in the disease-43, we identified in AD, and tau pathology, and tau, and tau, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "CARE-009",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the nutritional management approach for ALS patients.",
      "response": "\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-010",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe neurostimulation therapy for ALS and the evidence supporting its use.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research, and research, and the use of the importance of the need for the development of the field, and clinical trials.\n\n\n\n\n\nand the study,\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-011",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the investigation of lithium as a potential ALS treatment and the clinical evidence.",
      "response": "\n\n\n\nThe study, we have been identified in the disease. The most common genetic mutations in the disease, and FTD, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-012",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the detailed presynaptic mechanism by which riluzole reduces glutamate excitotoxicity.",
      "response": "\n\n\n\n\n\n\n\n\n, we investigated the role of the potential therapeutic potential therapeutic potential in the development of the development of the development of the development of the development of the treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a comprehensive studies, we identified a comprehensive research that the clinical trials, we have been developed a comprehensive research.\n\n\n\nand the study, we have demonstrated that the potential for the importance of the use of the development of the treatment in the future research.\n\n\n\n\n\n\n\n\n, we have a comprehensive studies, we have a comprehensive research, we have a comprehensive studies, we identified a comprehensive research on the clinical trials, we have been developed a comprehensive research and clinical trials for the study, we use of the limitations.\n\n\n\n\nand the study, we investigated the importance of the understanding of the potential in the need to evaluate the future research.\n\n\n\n\n\n, we have a comprehensive research on the current studies, we have been developed a comprehensive research and clinical trials, we will be available for the use of the limitations, we will be used to identify the development of the importance of the understanding of the treatment.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have a systematic review, we have a comprehensive studies, we have been developed a comprehensive research and clinical trials, we use of the limitations for the data, we will be available in this study.\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive study, we have a comprehensive research, we have a comprehensive research.\nThe study, we have been developed a comprehensive research and clinical trials, we have a comprehensive studies.\nthe data, we will be available in this study, we will be used to evaluate the importance of the future research.\n\n",
      "tokens_generated": 397,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-013",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the recommended dosage and administration schedule for riluzole in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-014",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the rationale and clinical evidence for memantine in ALS treatment.",
      "response": "\n\n\n\n\n\n\n, we have a common genetic and disease.\n\n\n, we investigated the role of the disease progression of the disease.\n\n\n\n, we found that the most common mutations in the disease. We identified a rare neurodegenerative diseases, we have a common mechanisms, we have a common genetic and disease, and FTD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau aggregation, and tau pathology.\n\n, we identified in AD, we have been reported that the most common mutations in AD pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau pathology, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-015",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Trace the FDA regulatory timeline for AMX0035 (Relyvrio) from the CENTAUR trial through its withdrawal.",
      "response": "\n\n\n\n\n\n\nThe study, we used the first study, we performed using a model. The data were conducted using the data. The data collection, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the data, we used the data from the data analysis of the first study, we performed using a model, we used the data.\n\n\n\nThe data collection, we used the data, we used the data, we conducted the data, we used the data, we set the data, we used the data. The data were obtained from the data, we used to assess the data.\n\n\n\n\n\n\n\nthe data, we performed using the model was performed using a model, we used the data, we first study, we used the data, we conducted using the data, we set using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data, we used the data, we used the data, we used the data were performed using the data, we used the data, we first study, we used the model was conducted using a comprehensive analysis, we set the data. The data, we used the data, we used the data collection, we used the data, we used the data, we used the data, we used the data, we performed using the data, we used the data, we first study, we used the data, we conducted the data.\n\n\n\n\n\n\n\n\n\nthe data, we set the data, we used the data, we will be available data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we will be performed using the data, we will be conducted using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe data, we will be used to evaluate the data, we will be available in the data, we will be performed using the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we will be conducted using the data\n\n\n\nthe data\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the data\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-016",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe how edaravone is administered to ALS patients and any changes to its delivery method.",
      "response": "\n\n\n\n\nThe study, we have a common in the disease progression of the disease. The most common genetic mutations in the disease progression of the disease.\n\n\n\n\nand the most common genetic variants in the most common mutations in the most common in the most common mutations in the most common in the disease.\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a rare diseases, we have been identified a common and the disease.\n\n\nThe most common genetic mutations in the most common proteins, we have a common gene expression of the RNA-binding protein (43) and FUS, which are known to be associated with the RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-017",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the detailed molecular mechanism of edaravone's antioxidant action in ALS.",
      "response": "\n\n\n\n\n\n\n, we have a common in the most common and the most common mechanisms of the disease.\n\n\n\n\nThe most common genetic mutations in the most common proteins, we identified in the most common proteins, which are known to be associated with the most common proteins that are essential for the development of the disease.\n\n\n\n\n\nand the most common pathways, we have a common mechanisms, we have been identified a common proteins, and RNA-binding protein (Figure 5). The RNA-associated proteins, we investigated the RNA-binding proteins in the RNA-binding proteins, which are known to the RNA-binding proteins. We found that the RNA-binding proteins, we observed in the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding protein (Figure 5).\n\n\n\nand the RNA-binding proteins, we identified a common RNA-binding proteins, which are known to be associated with the RNA-binding proteins. We have a complex of RNA-binding proteins that the RNA-binding proteins in the RNA-binding proteins, and RNA-binding proteins, and RNA-binding protein (Figure 5).\n\n\nand the RNA-binding proteins, we identified the RNA-binding proteins, we found that the RNA-binding proteins, which are known to the RNA-binding proteins. We have a complex of RNA-binding proteins in the RNA-binding proteins, which are essential for the RNA-binding protein. The RNA-binding proteins, we investigated the RNA-binding proteins that the RNA-binding proteins that the RNA-binding proteins and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, which are essential for RNA-binding proteins in the RNA-binding proteins.\n\n\n\nand the RNA-binding protein-binding proteins, we identified a complex, we investigated the RNA-binding proteins that the RNA-binding proteins that the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, which are essential for the RNA-binding proteins in the RNA-binding proteins. We have been shown that the RNA-binding protein-binding proteins that the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins.",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-018",
      "category": "drug_treatment",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the drugs used to treat muscle cramps in ALS patients.",
      "response": "\n\n\n\n\n\n\n\n\n\n*\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 1,
      "is_coherent": false
    },
    {
      "question_id": "DRUG-019",
      "category": "drug_treatment",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the clinical investigation of celecoxib for ALS and its outcomes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n, we investigated the study, we identified in the study, we have been reported that the disease progression.\n\n\n\n, we found that the most common genetic variants in the disease. We also be associated with a rare diseases, we have a role of ALS.\n\n, we have a recent study, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DRUG-020",
      "category": "drug_treatment",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe cortexilin's neuroprotective mechanism and its clinical evidence in ALS treatment.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "GENE-011",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the OPTN (optineurin) gene and its role in ALS pathogenesis.",
      "response": "\n\n\nThe most common mutations in the most common variants in the aggregation of the protein, and the cytoplasm, which are known to be associated with the RNA-binding proteins. The RNA-associated proteins that are essential for the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding protein (Figure 5).\n\n\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein (Figure 1). The RNA-binding protein-binding protein-binding protein (Figure 5A) is a protein-binding protein (Figure 5B) and RNA-binding protein (Figure 5).\n\n\n\n\n\n\n\n\n\nand the RNA-binding protein (Figure 5).\n\n\n\n\nThe RNA-binding protein (Figure 5A) is the RNA-binding protein (Figure 5-43-binding protein (Figure 5A) and RNA-binding protein (Figure 5B), which is a protein (Figure 5). The RNA-binding protein (Figure 5A) is a protein (Figure 5).\nand the RNA-binding protein (Figure 5A) is a protein (Figure 5A) is a protein (Figure 5C) is a protein (Figure 5A) and RNA-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-binding protein (Figure 5B).\nand the RNA-binding protein (Figure 5-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (Figure 5).\nand TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (Figure 5A) is a TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-012",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the role of NEK1 in ALS and how it was identified as a risk gene.",
      "response": "\n\n\nThe most common mutations in the most common mutations in the disease, which is a common to be associated with the disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the most common mutations in the most common genetic variants of the most common mutations in the most common mutations in the most common mutations in the most common mutations in the disease progression of the disease, and disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe most common mutations in the most common mutations in the most common mutations in the most common genetic variants in the most common mutations in the most common mutations in the most common mutations in the most common proteins that are known to be associated with the disease, and disease.\n\n\n\n\n\n\n\n, we have a rare neurodegenerative diseases, we have been identified in the most common mutations in the disease progression of the disease.\n\n\n\n\nand the most common genetic variants in the disease, we have been identified by the disease, we have a common genetic and disease, we have been identified a common mutations in the disease. We have a rare neurodegenerative diseases, we have been identified a rare neurodegenerative diseases, we have a rare diseases, we have a common genetic and disease, we have been identified a rare neurodegenerative diseases, we have been identified in the disease, we have a common genetic variants in the disease, and disease, and FTD, and tau pathology.\n\nand the most common mechanisms of AD, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-013",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the C9orf72 repeat expansion including the repeat unit, normal vs pathogenic repeat counts, and inheritance.",
      "response": " The second-old controls, and the same of the most common than the time.\n\n\n\n\n\nThe first study was performed using the first study. The study, we used to assess the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we identified a comprehensive analysis of the data, we conducted the data from the data, we performed the data, we performed using the data. We analyzed the data, we used the data, we used the data, we used the data, we used the data, we used to evaluate the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we identified a comprehensive studies, we performed the model of the first study, we conducted the data from the data, we used the data, we used the data, we used the data, we used the data. We have a comprehensive analysis of the data, we used the data, we used the data, we used the data, we identified a comprehensive studies, we performed the data, we used the study, we conducted the data from the data, we used the data, we used the data, we used the data, we used the data.\n\n\n\n\n\n\n\n\n\n\nthe model of the data, we have a comprehensive analysis, we identified a single-based sequencing (Supplementary Table S1) and the first-specific RNA-seq (Figure 5). The results were performed using the dataset. We used for the data, we used to identify the data.\n\n\n\n\n\n\n\nThe data, we conducted the data, we used the data, we identified a single-seq analysis of the data.\n\n\n\n\nTo assess the RNA sequencing (Supplementary Table S1). The results were performed using the RNA sequencing. We performed using the RNA-seq and RNA sequencing (Figure 5).\n\n\n\n\n\nWe performed using the RNA-seq data, we used for RNA sequencing (Figure 4).\n\nthe RNA-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-014",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe VCP mutations and their role in ALS and inclusion body myopathy with Paget disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "GENE-015",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Discuss the genetic contributions to sporadic ALS cases.",
      "response": "\n\n\n\n\n\n\n\n\n\n, we have a role in the disease.\n\n, we investigated the most common genetic and the disease progression of the disease. We have been identified a rare diseases, we have a common mechanisms that the disease, and FTD, and FTD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-016",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe SQSTM1/p62 and its connection to ALS pathogenesis.",
      "response": "\n\n\n\n\nThe most common in the most common mutations in the disease, and FTD, and tau pathology, and tau, and tau aggregation, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "GENE-017",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe UBQLN2 mutations and their pathological consequences in ALS.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression. We have a common genetic changes in the disease. The most common genetic variants in the disease progression of the disease.\n\n\n\n\n\n\n\nThe most common genetic mutations in the disease, we identified a rare neurodegenerative diseases, we have been reported that the disease.\n\nand the disease, we have a role in the disease, we found that the disease, we have a common genetic and FTD, we investigated the disease progression of the disease. We have a recent study, we have a novel insights into the disease.\n",
      "tokens_generated": 124,
      "is_coherent": true
    },
    {
      "question_id": "GENE-018",
      "category": "gene_mutation",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain the role and timing of genetic counseling for ALS patients and their families.",
      "response": "\n\n\n\n\n\nThe study, we have a recent study, we identified a comprehensive research that the need to be available in this study.\n\n\n\n\n\n\n\n\n\n, we have been developed a comprehensive research on the current research that the clinical trials, we have been used for ALS.\n\n, we have a systematic review, we have a comprehensive research, we have a comprehensive research and clinical trials, we have been identified in the study. The study, we have a comprehensive research, we have a comprehensive research, we have developed a comprehensive research on the data from the study, and the study, and to identify the need for ALS.\n\n\n\n",
      "tokens_generated": 141,
      "is_coherent": true
    },
    {
      "question_id": "GENE-019",
      "category": "gene_mutation",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe ATXN2 intermediate repeat expansions and their role as an ALS risk factor.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "GENE-020",
      "category": "gene_mutation",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the MNDF1 gene, its protein product, and the ALS clinical presentation caused by MNDF1 mutations.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-011",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List and describe the upper motor neuron (UMN) signs that clinicians evaluate when diagnosing ALS.",
      "response": "\n\n\n\n\nThe study, we have a comprehensive research on the clinical trials.\n\n\n\n\n\nThe study, we have been identified by the study, we have a comprehensive data from the study. We have a single-based approach for the first study, and the study, and the study, and the study, and the study, and the study, and the study, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\nThe study, we have been identified in this study, we have a comprehensive research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials. The study, we have been developed the data, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\n",
      "tokens_generated": 267,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-012",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the electromyographic findings that support ALS diagnosis, including both spontaneous and motor unit changes.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-013",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the key clinical and diagnostic differences between cervical myelopathy and ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "DIAG-014",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe multifocal motor neuropathy (MMN) and explain why differentiating it from ALS is clinically important.",
      "response": "\n\n\nThe most common in the most common genetic mutations in the disease, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-015",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain why MRI is performed during the ALS diagnostic workup and what findings are expected.",
      "response": "\n\n\n\nThe study, we have a comprehensive research that the study of the first study, we have been identified in the clinical trials. The study, we have been reported that the study, we have a single-based approach for the study, we have a comprehensive studies.\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive research on the study, we have a comprehensive and clinical trials, we have a comprehensive research. The study, we have been identified in the study, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\nand the study, we used a comprehensive research, we have developed a comprehensive research that the study, we will be available in the study.\n",
      "tokens_generated": 153,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-016",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe primary lateral sclerosis (PLS) and explain how it is distinguished from ALS.",
      "response": "\n\nThe study, we have a recent study, we found that the disease progression of the disease. The study, we investigated the clinical trials, we have been identified in the clinical trials. We have a comprehensive research on the study, we have been developed to identify the importance of the future research.\n\n\n",
      "tokens_generated": 65,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-017",
      "category": "diagnostic_criteria",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the body regions that diagnostic criteria use to classify the extent of ALS spread.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a single-based sequencing (ALS) and RNA-binding protein in the RNA-43, which is a common RNA-binding protein-binding protein. The RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-018",
      "category": "diagnostic_criteria",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare the Gold Coast criteria to the El Escorial and Awaji criteria and explain what the Gold Coast criteria simplified.",
      "response": "\n\n\nThe study, we have been reported that the importance of the use of the impact on the development of the patient. The study, we have a comprehensive research is needed to be available in the study.\n\n\n\n\n\n\n\n\nThe study, we have a systematic review, we have a recent study, we have a study, we have been identified a comprehensive studies, we have been reported that the study, we have a more common genetic and clinical trials. The study, we have a comprehensive research is a comprehensive understanding of the literature, we have a comprehensive research on the data from the study, we will be available in this study.\n\n\n\nThe study, we have a systematic review, we have been identified a comprehensive studies, we have a comprehensive studies, we have a comprehensive and clinical trials, we have been developed a comprehensive research.\n\n\n\n\n\n",
      "tokens_generated": 184,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-019",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe progressive muscular atrophy (PMA) and its relationship to the ALS spectrum.",
      "response": "\n\n\n\nThe study, we investigated the first-based approach for the potential in the need for the importance of the development of the future research.\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have a comprehensive studies, we have been developed a comprehensive and clinical trials, we will be available to identify the use of the understanding of ALS.\n",
      "tokens_generated": 81,
      "is_coherent": true
    },
    {
      "question_id": "DIAG-020",
      "category": "diagnostic_criteria",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the Brinkworth ALS staging system and how it classifies disease progression.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-011",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the dexpramipexole Phase 3 trial for ALS and the reasons for its failure.",
      "response": "\n\n\nThe study, we used a comprehensive research. The study, we identified a comprehensive studies, we have been identified in the data. We have reported that the importance of the importance of the development of the importance of the importance of the future research.\n\n\n\n\n\n\n\nThe study, we have a comprehensive research on the study, we have been developed a comprehensive understanding of the study, we have been identified in this study, we have been identified in the data. The study, we have been reported that the study, we have a comprehensive studies, we have been identified a comprehensive research.\n\n\n\nThe study, we have been identified a comprehensive and the study, we have a comprehensive studies, we have a comprehensive research, we have a comprehensive research, we have a comprehensive understanding of the data from the study, we have a comprehensive studies, we have been developed a comprehensive research. The study, we have been published in this study, we have a comprehensive research on the study, we have a comprehensive research and the data, we have a comprehensive research.\n\n\n\n\n\nThe study, we have a comprehensive research, we have identified a comprehensive studies, we have a comprehensive research, we have a comprehensive research that the study, we have been developed a comprehensive understanding of the importance for the data from the data, we will be available in this study.\n\n\n\n\n",
      "tokens_generated": 288,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-012",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the investigation of ceftriaxone for ALS treatment and the results of the clinical trial.",
      "response": "\n\n\n\nThe study, we identified a comprehensive research that the current studies, we have been reported that the importance of the role in the development of the disease progression.\n\n\n\n\n\n\n\n\nand recent study, we investigated the study, we have a comprehensive research on the potential of the clinical trials.\n\n\n\nThe study, we have identified a comprehensive research and clinical trials, we have been developed a comprehensive research.\n\n\n",
      "tokens_generated": 95,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-013",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain why the ALSFRS-R is the dominant primary endpoint in ALS trials and what its limitations are.",
      "response": "\n\n\nThe study, we have a recent study, we have a comprehensive research that the clinical trials for the study. The study, we have been identified a comprehensive research on the study, we will be available to identify the importance of the future research.\n\n\n",
      "tokens_generated": 56,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-014",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the minocycline clinical trial for ALS and explain the surprising outcome.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "TRIAL-015",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the ATLAS trial of tofersen and its significance for presymptomatic ALS carriers.",
      "response": "\n\n\n\n\n\n, we have been reported that the disease progression in the disease. The most common genetic mutations in the disease.\n\n\n\n\n, we identified a rare neurodegenerative diseases, we have a common genetic and disease. We have a rare neurodegenerative disease, we found that the disease-43, we observed that the most common variant in the disease.\n\n\n\n\n\nand the most common genetic variants of the disease, we have been reported in the disease.\n\n\n\n\n\n\nThe most common mutations in the most common genetic mutations in the most common genetic mutations in the disease, we identified in the disease-specific TDP-43 pathology, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-016",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how biomarkers are used to select and stratify patients in contemporary ALS clinical trials.",
      "response": "\n\n\n\n\nThe study, we have a comprehensive research on the need for AD.\n\n\n\n\n\nand the use of AD, we have been identified a common genetic and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-017",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the NCT08442197 clinical trial of neurogenix for ALS, including the study design and primary results.",
      "response": "\n\n\n\n\n\n\n\nThe study, we have been identified in the study. The study, we investigated the study, we have a comprehensive research that the study, we have not be used to identify the importance of the development of the future research.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have been developed a comprehensive studies, we have identified in this study, we have been identified in the study, we have a comprehensive understanding that the study. We have a comprehensive research on the study, we have been reported that the study, we have a comprehensive research. The study, we have been identified a comprehensive research and clinical trials, we have a comprehensive studies, we have been developed a comprehensive research.\n\n\n",
      "tokens_generated": 156,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-018",
      "category": "clinical_trials",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "List the key obstacles to recruiting and retaining patients in ALS clinical trials.",
      "response": "\n\n\n\n\n\n\n\n, we have been identified a common genetic and disease progression. The study, we investigated the role of the disease progression of the disease progression.\n\n\n\n\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n\n, we found that the most common genetic variants in the disease, we have identified a common genetic and the disease-specific TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-019",
      "category": "clinical_trials",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the gene therapy strategies currently in clinical trials for ALS.",
      "response": "\n\n\n\n\n\n\n, we have been identified a common genetic and genetic and disease progression.\n\n\n\n\n\n, we investigated the role of the development of the disease.\n\n\n\n\n\n, we have been reported that the most common genetic mutations in the disease.\n\n\n, we have a rare neurodegenerative diseases, we have a common mechanisms, and disease, and disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, and tau pathology, and tau, and tau, tau, tau, and tau, tau, tau, and tau, tau, tau, tau, tau, and tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TRIAL-020",
      "category": "clinical_trials",
      "difficulty": "hard",
      "is_trap": true,
      "prompt": "Describe the BENEFIT-ALS platform trial design and its contributions to ALS trial methodology.",
      "response": "\n\n\n\nThe study, we conducted a comprehensive research on the clinical trials. The study, we have been identified in this study, we have been developed a comprehensive studies.\n\n\n\n\n\nand the study, we used the study, we have a comprehensive data from the study, we will be available for the data.\n\n\n\n\nThe study, we have been published, we have been reported that the first study, we have a single-based clinical trials, we have been developed to evaluate the use of the importance of the future research.\n\n\n\n\n\n\n\nand the study, we have been identified a comprehensive studies, we have a comprehensive understanding of the data, we have been used for the data, we will be available in this study.\n\n",
      "tokens_generated": 163,
      "is_coherent": true
    },
    {
      "question_id": "MECH-011",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Explain the non-cell-autonomous toxicity of astrocytes in ALS and the key experimental evidence.",
      "response": "\n\n\n, we investigated the role of the potential for the development of the importance of ALS. We have a novel mechanisms that the molecular modifications, we identified a role in the aggregation of the formation of the aggregation. The most common proteins, we have been identified in the cytoplasm, which are essential to the aggregation and the aggregation of the aggregation of the accumulation of the aggregation.\n\n\n\n\nand the development of the most common proteins, we have been identified a crucial for ALS. We have a role in the most common mechanisms that the most common proteins, we have a complex, we have been identified in the cytoplasm, we have been identified in the formation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation and the aggregation of the aggregation of the aggregation of the aggregation of the ALS.\n\n\n\n\n\nand the most common proteins that the most common proteins, we have a role in the aggregation of the aggregation of the aggregation of the aggregation of the formation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation of the aggregation. The RNA-binding protein and RNA-associated proteins, which are essential for the RNA-binding proteins in the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins.\n\n\n\nand the RNA-associated proteins, we have a crucial for the RNA-binding protein-binding proteins, which are essential for the RNA-binding proteins in the RNA-binding proteins. We identified a complex, we investigated the RNA-specific RNA-binding proteins that the RNA-binding proteins and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding protein-binding proteins, which are essential for RNA-binding proteins.\n\n\n\n\nand the RNA-binding proteins, we identified a crucial role in the RNA-binding proteins that the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins, and RNA-binding protein, and RNA-binding proteins, which are essential for the RNA-binding proteins.\n\n\nand the RNA-binding proteins, we identified in the RNA-binding proteins that the RNA-binding proteins, and RNA-binding proteins, and RNA-binding proteins,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-012",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe stress granules and their connection to ALS disease mechanisms.",
      "response": "\n\n\n\n\n, we investigated the role of ALS.\n\n\n\n\n\n, we have a role in the disease progression of the disease.\n\nand the disease, we found that the disease progression of the disease progression of the disease.\n\n\n\n, we have a common genetic and FTD, we identified a rare neurodegenerative diseases, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology. We found that the tau pathology, we have been reported that the aggregation of tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology in AD, and tau pathology, and tau pathology, and tau pathology.\n\nand tau, we investigated the role of tau pathology in AD pathology in AD pathology in AD, tau pathology in AD, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology.\nand tau pathology, we investigated the aggregation of tau pathology, we have been identified a role in AD, tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology.\n\nand tau pathology, tau aggregation of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau, tau pathology, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau aggregation, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-013",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the role of nuclear pore complex (NPC) defects in ALS and the evidence linking them to C9orf72 disease.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "MECH-014",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain how defects in axonal transport contribute to ALS pathology.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression and disease. We have a role in the disease progression of the disease, we found that the disease progression of the disease.\n\n\n\n\nThe disease is a common mechanisms underlying mechanisms for the pathogenesis of the development of the disease.\n\n\n\n\nand the disease is a rare neurodegenerative diseases, we have a common and disease, we investigated the disease.\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a role in the disease, we have been identified in the disease, we have a common genetic mutations in the disease progression of the disease.\nand the disease, we have a rare neurodegenerative diseases, we have a common genetic and disease, we have a common mechanisms that are known to be associated with ALS.\n, we have a rare neurodegenerative disease, we have been identified in the disease, we have a common genetic mutations in the disease.\n\n, we have a common mutations in the disease, we investigated the disease, we have a common genetic and FTD, we have a common genetic and FTD, we have a common tau pathology in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\nand tau pathology, we identified a role of tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau, tau pathology, tau pathology, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-015",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the mitochondrial abnormalities found in ALS motor neurons and their pathological consequences.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the disease progression of the disease.\n\n\n\n\n\n, we have a common TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-016",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Explain the prion-like spreading mechanism proposed for ALS protein aggregates.",
      "response": "\n\n\n\n\n\n, we investigated the potential of the role in the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the disease.\n\n\n\n\n\n\n\n\n\n\n, we have a common mechanisms that the role in the most common genetic and disease progression of ALS.\n\nand the most common mutations in the disease, we have been identified in the disease. We have a rare neurodegenerative diseases, we have a common mutations in the disease, we have a common disease.\n\n\n\n\n\n\n, we investigated the disease, we have a role of the disease progression and disease, we have a common genetic changes in the disease.\n\n\nand the disease, we identified a common mechanisms that the disease-associated TDP-43 aggregation of TDP-43 pathology, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-017",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how microglial cells contribute to ALS motor neuron damage.",
      "response": "\n\n\n\n\n, we investigated the role of the disease progression and disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we identified a role in the disease, we have been reported that the disease progression of the disease.\nand the disease is a common mutations in the disease.\n\n\n\n, we found that the most common TDP-43 aggregation of TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-018",
      "category": "disease_mechanisms",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe dipeptide repeat proteins produced by C9orf72 repeat expansions and their mechanisms of toxicity.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "MECH-019",
      "category": "disease_mechanisms",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Explain the excitotoxicity hypothesis in ALS and the evidence supporting it.",
      "response": "\n\n\n\n\nThe role of the development of the development of the development of the disease progression, and disease.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a common mechanisms that the disease.\nand the most common mutations in the disease progression of the disease.\n\n\n\n\n, we have been identified a rare diseases, we have a common genetic and disease, and FTD, and FTD, and AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "MECH-020",
      "category": "disease_mechanisms",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the CREB4 signaling cascade and its proposed neuroprotective role at the neuromuscular junction in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-011",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the major ALS genes in the order they were discovered, with approximate dates.",
      "response": "\n\n\n\nThe authors have a single-based approach for the first study. The study, we used the data from the model of the first study. We identified a comprehensive studies, we performed the data, we conducted using the data, we used the data.\n\n\n\n\n\n\n\n\n\nand the study, we used the data, we have a single-based approach for the data, we will be used to evaluate the model.\n\n\n\n\n\n\n\n\nthe first study, we have been identified in the data, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive research. We have a comprehensive understanding of the data, we have a single-based approach for the data, we will be used to evaluate the data.\n\n",
      "tokens_generated": 164,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-012",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State the year the C9orf72 GGGGCC repeat expansion was identified and name the research groups involved.",
      "response": "\n\n\n\n\nThe study, we used the first study, we performed using the data from the data. The study, we conducted a comprehensive analysis of the data, we have been reported that the data. We also be considered for the data, we have a significant differences in the data.\n\n\n\n\n\n\n\n\nand the study, we used the first study, we performed the study, we identified a single-based sequencing (Supplementary Table 1). The study, we identified a comprehensive analysis of the data from the data, we identified a single-specific RNA-seq and RNA-binding protein. We have a single-type RNA-43-binding protein (Figure 5).\n\n\n\nTo assess the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5). The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5-43-43) and RNA-binding protein (Figure 5-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43 (Figure 5).\n\n\n\n\n\n\n\nand the RNA-binding protein-associated TDP-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-43-",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-013",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "List the major ALS diagnostic criteria systems in chronological order with their years of publication.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the first study, we have a significant differences in the disease progression.\n\n\n, we found that the most common genetic and the clinical trials, we have been identified in the disease.\n\n\n\n, we have a recent study, we have a rare neurodegenerative diseases, we have a common genetic diagnosis of the disease. We have a common genetic mutations in the disease, we have a significant differences in the disease progression, and FTD, and AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, and tau, tau pathology, and tau, tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, tau, and tau, tau, tau, and tau, and tau, and tau, tau, and tau, and tau, tau, and tau pathology, tau, tau, tau, and tau, and tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-014",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when TDP-43 was identified in ALS pathology and explain the significance of this discovery.",
      "response": "\n\n\n\nThe study, we found that the disease progression of the disease progression in the disease. The study, we have a significant correlation between the disease progression of the disease. We also reported that the most common genetic changes in the disease.\n\n\n\n\n\n\n\n\nand the first study, we identified a rare neurodegenerative diseases, we investigated the role of the disease and FTD, we found that the disease, we have been identified in AD pathology in AD. The study, we have a significant correlation between the most common genetic diagnosis, we have a recent study, we have a more common tau pathology in AD.\n\n\nand the first study, we investigated the role of AD, we have a role in AD pathology in AD and tau pathology in AD, we identified in AD pathology in AD pathology, we found that tau pathology in AD pathology in AD pathology, and tau pathology, and tau pathology, and tau pathology in AD. We also associated with AD, we found that tau pathology, we investigated the tau pathology in AD, we have a role of tau pathology, tau pathology in AD pathology in AD pathology in AD, tau pathology in AD pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology in AD.\n\n\nand tau pathology in AD, we found that tau pathology in AD, we identified the aggregation of tau pathology in AD, we have a role in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD and tau pathology in AD. We also present study, we found that tau pathology in AD, we found that tau pathology in AD pathology in AD, we identified a significant correlation between tau pathology, we have a role of tau pathology in AD pathology in AD pathology in AD pathology in AD pathology, tau pathology in AD pathology in AD and tau pathology in AD.\n\n\n\n\nand the aggregation of tau pathology in AD pathology in AD pathology in AD, we found that tau pathology in AD pathology in AD pathology in AD pathology in AD, we investigated the tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD and tau pathology in AD pathology. We have a role in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD, we found that tau pathology in AD pathology in AD pathology in AD, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-015",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State when the Ice Bucket Challenge took place and its fundraising impact for ALS research.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "TEMP-016",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "List all FDA-approved ALS-specific therapies in the order they were approved, with dates.",
      "response": "\n\n\nThe study of the study, we have a comprehensive studies, we have been identified in the study. The study, we have a single-based approach for the study, and clinical trials, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 59,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-017",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "State when the SOD1 transgenic mouse model for ALS was created and by whom.",
      "response": "\n\n\n\n\n\n\n\nThe study, we used to identify the role of the disease progression.\n\n\n\n\n\n\nand the first study, we investigated the study, we have a comprehensive studies, we identified a comprehensive research on the clinical trials.\n\n\n\n\n\n",
      "tokens_generated": 62,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-018",
      "category": "temporal_accuracy",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the year tofersen (Qalsody) received FDA approval and the type of approval granted.",
      "response": "\n\n\n\n\nThe study, we used to assess the model. The data from the first study, we conducted a comprehensive analysis, we performed using the data, we used the data, we identified a single-based data. We used the data, we used the data, we used the data, we used the data, we used the data, we used the data, we have been used to evaluate the model.\n\n\n\n\nThe study, we conducted the data from the data, we performed the data, we used a comprehensive data, we identified a single-based data, we used the data, we used the data, we used for each sample size of the data. The data, we used the data, we have a model, we used the data, we used to evaluate the data from the data, we performed using the data.\n\n\n\n\n\nThe data, we used the data, we used the data, we used the data, we used the data, we used the data, we used the data, we have a single-based data, we will be used to evaluate the data. We will be used for each sample size of the data, we will be available in the data.\n\n\n\n\n\n\n\n\n\nThe data, we will be performed using the data, we will be used to assess the data, we have a single-based data from the data, we will be used to evaluate the data.\n\n\n\nthe dataset, we will be used for each sample size of the data, we will be used to identify the data.\n\n\n\n\n\n\n\n\n\n\n\nThe data, we will be performed using a model, we have a single-based sequencing (see Table 1).\n\n\n\n\n\nWe will be used to evaluate the data.\n\nthe dataset, we used for the data from the data, we will be available in the data.\n\n\n\n\n\nThe study, we will be performed using the data, we have a single-based sequencing (Figure 1).\nTo assess the data, we will be used to identify the data. We will be used the data, we will be used for the data from the dataset, we will be used to evaluate the data, we will be available in the data.\n\n\n\n\n\nThe data, we have a single-based sequencing data, we will be performed using the data. The data, we will be performed",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-019",
      "category": "temporal_accuracy",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "State when FUS gene mutations were discovered in ALS and describe the significance.",
      "response": "\n\n\n\n, we identified a single-specific RNA-binding protein (43) and RNA-binding protein (43 (43 (43), and RNA-43, and RNA-associated TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "TEMP-020",
      "category": "temporal_accuracy",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Determine whether the C9orf72 hexanucleotide repeat expansion was identified as a cause of ALS in 2006.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "EPI-011",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Compare ALS incidence rates across Europe, Asia, and the Americas.",
      "response": "\n\n\n\n\n\n\n\nThe study of the study, we have been reported that the role in the importance of the development of the impact on the context of the treatment.\n\n\n\n\n\n\n\n\nand the first study, we have a comprehensive studies, we have been identified in this study, we have been reported that the study.\n\n\nThe study, we have been reported that the study, we have been reported that the study, we have been reported that the study, we have been reported that the study, we have a significant differences between the importance of the impact on the role in the context of the importance of the importance of the importance.\n\n\n\n\n\n\n\nThe study, we have been identified a result in this study, we have been shown that the study, we have a significant differences in the first study, we found that the study, we have been reported that the study, we have a role in the study, we have a significant differences between the importance of the study.\n\nand the study, we have a result in this study, we have a significant differences between the study, we have a significant differences in the first study, we have a significant differences in the study, we have been reported that the study, we found that the study, we have a significant correlation between the study.\n\n\n\n\nand the study, we have a result in the study, we have a role in the study, we have a significant differences in the first study, we have a significant differences in the study, we have been reported that the study, we found that the study, we have a significant differences between the study, we investigated the importance of the study.\n\n\n\nand the study, we have a role in this study, we have a result in the first study, we have a role in the study, we have a significant correlation between the study, we have been reported that the impact on the relationship between the study, we have a significant differences in the importance of the study.\n\n\n\n\nand the study, we have a significant differences in the study, we investigated the first study, we review, we have a role in the study, we have a result in the study, we have been reported that the impact on the context of the study, we found that the importance of the study.\n\n\n\n\nThe study, we have a significant differences between the study, we investigated the study, we have a comprehensive studies",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-012",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological evidence for increased ALS risk among military veterans beyond the Gulf War.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-013",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the frequency and spectrum of cognitive changes in ALS patients.",
      "response": "\n\n\n\n, we investigated the study, we have a disease progression of the disease.\n\n\n\n\n\n\n\n, we have a common genetic mutations in the disease, and FTD, and tau pathology, and tau, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-014",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Compare survival statistics and prognosis between bulbar-onset and limb-onset ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "EPI-015",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe how age relates to ALS risk and what the peak incidence age range is.",
      "response": "\n\n\nThe study, we investigated the study, we used a comprehensive research that the study. We have a comprehensive studies, we have a comprehensive research on the study, we identified a comprehensive research that the study, we have a comprehensive research.\n\n\n\n\n",
      "tokens_generated": 56,
      "is_coherent": true
    },
    {
      "question_id": "EPI-016",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "List the environmental and occupational risk factors that epidemiological studies have associated with ALS.",
      "response": "\n\n\n\nThe study, we identified a comprehensive research, we identified a common genetic testing of the first study. We used the study, we identified a comprehensive data from the study, we identified a comprehensive analysis of the study, we have a comprehensive data. The study, we identified a comprehensive studies, we identified a comprehensive studies, we have a comprehensive studies, we have a comprehensive research on the clinical trials, we will be available for the study.\n",
      "tokens_generated": 94,
      "is_coherent": true
    },
    {
      "question_id": "EPI-017",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the historically documented ALS high-incidence clusters in the Western Pacific region.",
      "response": "\n\n\n\n\n\n\n\n\n\n, we investigated the first study, we have a role of the impact on the importance of the potential for the role in the role in the role in the role in the context.\n\n\n\n\n\n\n\n\n\nand the first study, we found that the study, we also be associated with the study, we have a significant differences between the most common in the first study.\n\n\n\n\n\n\n\n\nThe study, we present study, we identified a role of the first study, we observed that the first study, we investigated the impact on the importance of the relationship between the model.\nand the first study, we have been reported that the first study, we found that the first study, we also be considered a significant differences in the first study, we present in the role in the first study.\n\n\n\n\n\n\n\n\nThe results, we observed in the first study, we investigated the study, we have a correlation between the first study, we have a significant differences in the first study, we found that the relationship between the model of the first study, we present study, we also be considered a role in the importance of the impact on the study.\n\n\nand the study, we have a result in the study, we have a significant differences in the first study, we observed in the first study, we found that the study, we investigated the model, we have a correlation between the results, we also be considered a role for the importance of the impact on the importance of the heterogeneity.\n\n\n\n\n\nand the study, we present study, we have been reported that the study, we review, we have a significant differences in the first study, we found that the study, we have a correlation between the study, we also be considered a role in the model. We have a result in the study, we will be more likely to be considered for the importance of the impact on the importance of the context of the data.\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we review, we have been reported that the study, we have a significant differences between the study, we have a result in the study, we have a significant correlation between the first study, we also be observed in the study, we found that the study. We present study, we have a significant differences in the study, we have a significant differences in this study, we have been reported that the",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-018",
      "category": "epidemiology",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "State the sex ratio in ALS incidence and describe how it varies by disease type.",
      "response": "\n\n\n\nThe study, we have a significant differences between the disease. We found that the most common genetic changes in the disease progression of the disease. The results suggest that the role in the role in the disease progression of the disease progression in the disease progression of the disease progression and the disease.\n\n\n\n\n\nand the disease is a rare neurodegenerative diseases, we have a common genetic mutations in the disease.\n\nThe most common genetic mutations in the disease, we have been identified in the disease, we have a common genetic mutations in the disease, with ALS. The disease, we found that the most common genetic mutations in the disease progression of the disease.\n\n\n\n\nand the most common genetic variants, we have a rare neurodegenerative diseases, we have a common genetic and FTD, we have been identified in the disease. We have a rare neurodegenerative disease, we have a rare neurodegenerative disease, we have a rare neurodegenerative disease, we found that are associated with AD, and tau pathology, and tau pathology, and tau pathology, tau, tau, tau pathology, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "EPI-019",
      "category": "epidemiology",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the major ALS population-based registries and their contribution to epidemiological knowledge.",
      "response": "\n\n\n\n\n\nThe study, we have a comprehensive research on the clinical trials. The study, we have been identified in this study, we have been developed a comprehensive studies, we have a comprehensive research. We have demonstrated that the importance of the limitations, we have been reported that the future research.\n\n\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive research on the study, we have identified a comprehensive research and clinical trials, we have a comprehensive research. The study, we have a comprehensive research, we have a comprehensive research, we have been developed a comprehensive research, we have a comprehensive understanding of the data, we have a comprehensive research.\n\n",
      "tokens_generated": 146,
      "is_coherent": true
    },
    {
      "question_id": "EPI-020",
      "category": "epidemiology",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the epidemiological findings on ALS risk among Italian professional soccer players and state the incidence rate.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-011",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the multidisciplinary clinic model for ALS care and the evidence supporting its benefit.",
      "response": "\n\n\n\n\n\nThe study, we identified a comprehensive research on the study, we have been developed in the need to be available.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n, we have a systematic review, we have a comprehensive and clinical trials for the study, we have identified in the study, and clinical trials.\n\nThe study, we have been developed a comprehensive research on the literature.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we used the study, we have a comprehensive research on the study, we will be available for the data.\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have been identified in the study, we have developed a comprehensive and clinical trials, we have a comprehensive studies, we have been published, we have a comprehensive research.\n\n\n\n\n\nand the study, we have a comprehensive data from the study, we have a comprehensive research on the study, we will be available for the data collection, we have in the study, we have been developed a comprehensive and to evaluate the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have identified a comprehensive studies, we have a comprehensive research, we have a comprehensive research on the study, we will be available for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been developed a comprehensive and\nThe study, we have identified in this study, we have a comprehensive studies, we have a comprehensive research on the study, we will be available for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nthe study, we have a systematic review, we have been developed a comprehensive and the study, we have a comprehensive research.\nand the first study, we used a single-based approach to evaluate the model of the data.\nThe data, we will be available in the data.\n\n\n\n\n\n\nthe study, we have a comprehensive studies, we will be developed for the data.\n\n\n\n\n",
      "tokens_generated": 468,
      "is_coherent": true
    },
    {
      "question_id": "CARE-012",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the assistive communication technologies available for ALS patients who lose the ability to speak.",
      "response": "\n\n\n\n\nThe study, we conducted a comprehensive research on the clinical trials. The study, we have been identified in the study, and clinical trials, we have been developed a comprehensive research.\n\n\n\n\n\n\n\n\n\n\n, we used the study, we have a comprehensive studies, we have a comprehensive research. We have a comprehensive research, we have a comprehensive research on the study, we will be available for ALS.\n\n",
      "tokens_generated": 95,
      "is_coherent": true
    },
    {
      "question_id": "CARE-013",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the advance care planning issues that are particularly important for ALS patients.",
      "response": "\n\n\n\n\n, we have a common mechanisms of ALS.\n\n, we investigated the role in the importance of ALS.\n\n\n\nand the role in the disease progression and the development of the pathogenesis of ALS.\n\n\n\nThe most common genetic mutations in the disease.\n\n\n\n\n, we identified a rare diseases, we have been reported that the disease.\n, we have also known to be associated with ALS.\n, we have a rare neurodegenerative diseases, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, and tau, and tau, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "tokens_generated": 512,
      "is_coherent": true
    },
    {
      "question_id": "CARE-014",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the methods and timing for monitoring respiratory function in ALS.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-015",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe the cognitive-behavioral symptoms in ALS-FTD and the management approaches for patients and caregivers.",
      "response": "\n\n\n\nThe study, we have been identified a comprehensive research. The study, we have a recent study, we have demonstrated that the role of the importance of the potential for the development of the development of the development of the development of the development of the development of ALS.\n\n\n\n\nand the study, we have a novel therapeutic potential of ALS.\nThe study, we have been identified a comprehensive research on the clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and ALS.\n\n",
      "tokens_generated": 145,
      "is_coherent": true
    },
    {
      "question_id": "CARE-016",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the physical and psychological burden on ALS caregivers and available support resources.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-017",
      "category": "patient_care",
      "difficulty": "easy",
      "is_trap": false,
      "prompt": "Describe the contributions of speech-language pathologists to ALS patient care.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-018",
      "category": "patient_care",
      "difficulty": "hard",
      "is_trap": false,
      "prompt": "Describe when and how hospice and palliative care services are integrated into ALS management.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    },
    {
      "question_id": "CARE-019",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": false,
      "prompt": "Describe the types of pain experienced by ALS patients and the pharmacological approaches to management.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n",
      "tokens_generated": 512,
      "is_coherent": false
    },
    {
      "question_id": "CARE-020",
      "category": "patient_care",
      "difficulty": "medium",
      "is_trap": true,
      "prompt": "Describe the MotorGuard protocol for respiratory support in ALS patients, including its evidence base.",
      "response": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "tokens_generated": 0,
      "is_coherent": false
    }
  ]
}